1338482-09-9

Basic information

• Product Name: (S)-1-(6-fluoro-1-phenyl-1H-benzo[d]imidazol-2-yl)ethanamine
• Synonyms: (S)-1-(6-fluoro-1-phenyl-1H-benzo[d]imidazol-2-yl)ethanamine
• CAS NO: 1338482-09-9
• Molecular Weight: 255.295
• Mol File: 1338482-09-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 416.4±51.0 °C(Predicted)
• Density: 1.25±0.1 g/cm3(Predicted)
• CAS DataBase Reference: (S)-1-(6-fluoro-1-phenyl-1H-benzo[d]imidazol-2-yl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(6-fluoro-1-phenyl-1H-benzo[d]imidazol-2-yl)ethanamine(1338482-09-9)
• EPA Substance Registry System: (S)-1-(6-fluoro-1-phenyl-1H-benzo[d]imidazol-2-yl)ethanamine(1338482-09-9)

Safety Data

• Hazardous Substances Data: 1338482-09-9(Hazardous Substances Data)

Upstream product

• 367-31-7 4-fluoro-1,2-phenylenediamine 
• 1338482-06-6 (S)-tert-butyl 1-(6-fluoro-1H-benzo[d]imidazol-2-yl )-ethylcarbamate 
• 98-80-6 phenylboronic acid 
• 325-61-1 5-fluoro-N₁-phenylbenzene-1,2-diamine 
• 446-35-5 2,4-Difluoronitrobenzene 
• 322-68-9 4-fluoro-2-(phenylamino)nitrobenzene 
• 62-53-3 aniline 
• 1338482-07-7 (S)-tert-butyl 1-(6-fluoro-1-phenyl-1H-benzo[d]imidazol-2-yl)ethylcarbamate 

Downstream Products

• 1393180-59-0 (S)-N-(1-(6-fluoro-1-phenyl-1H-benzo[d]imidazol-2-yl)ethyl)-9H-purin-6-amine 

Relevant articles and documents

Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors

Lead optimization efforts resulted in the discovery of two potent, selective, and orally bioavailable PI3Kδ inhibitors, 1 (AM-8508) and 2 (AM-9635), with good pharmacokinetic properties. The compounds inhibit B cell receptor (BCR)-mediated AKT phosphorylation (pAKT) in PI3Kδ-dependent in vitro cell based assays. These compounds which share a benzimidazole bicycle are effective when administered in vivo at unbound concentrations consistent with their in vitro cell potency as a consequence of improved unbound drug concentration with lower unbound clearance. Furthermore, the compounds demonstrated efficacy in a Keyhole Limpet Hemocyanin (KLH) study in rats, where the blockade of PI3Kδ activity by inbibitors 1 and 2 led to effective inhibition of antigen-specific IgG and IgM formation after immunization with KLH.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.